| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/104303403322542275 |
| P698 | PubMed publication ID | 14633405 |
| P50 | author | Georg Varga | Q52767377 |
| P2093 | author name string | Wilhelm Bloch | |
| Stefan Kochanek | |||
| Nico Van Rooijen | |||
| Sabine Hertel | |||
| Gudrun Schiedner | |||
| Georg Varga | |||
| Volker Dries | |||
| Andrei Molojavyi | |||
| Marion Johnston | |||
| P2860 | cites work | Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation | Q22010150 |
| P433 | issue | 17 | |
| P921 | main subject | endothelium | Q111140 |
| Adenoviridae | Q193447 | ||
| hemodynamics | Q1642137 | ||
| P304 | page(s) | 1631-1641 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells | |
| P478 | volume | 14 |
| Q35618835 | Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases |
| Q36445557 | Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery |
| Q40424880 | Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma |
| Q33565630 | Adenoviral vector immunity: its implications and circumvention strategies |
| Q36419822 | Adenoviral vectors--how to use them in cancer gene therapy? |
| Q90122264 | Adenovirus Biodistribution is Modified in Sensitive Animals Compared to Naïve Animals |
| Q37191878 | Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. |
| Q33389860 | Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. |
| Q97525877 | Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection |
| Q40046781 | Adenovirus expressing mutant p27kip1 enhanced apoptosis and inhibited the growth of xenografted human breast cancer |
| Q33916572 | Adenovirus infection results in alterations of insulin signaling and glucose homeostasis |
| Q40815226 | Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors |
| Q40103248 | Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. |
| Q33771285 | Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo |
| Q33713324 | Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactions |
| Q40197207 | Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. |
| Q50977875 | Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy. |
| Q64378490 | Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses |
| Q34597583 | Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement |
| Q59351305 | Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting |
| Q34585554 | Current strategies and future directions for eluding adenoviral vector immunity |
| Q45865369 | Enhanced local delivery with reduced systemic toxicity: delivery, delivery, and delivery. |
| Q34153735 | Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model |
| Q33622711 | Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus |
| Q45875328 | Factors influencing retention of adenovirus within tumours following direct intratumoural injection. |
| Q35139196 | Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity |
| Q33881920 | Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. |
| Q55452882 | Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease. |
| Q37582126 | Helper-Dependent Adenoviral Vectors. |
| Q34982825 | Helper-dependent adenoviral vectors for liver-directed gene therapy. |
| Q36219334 | Helper-dependent adenoviral vectors in experimental gene therapy. |
| Q37945219 | Improving adenovirus based gene transfer: strategies to accomplish immune evasion |
| Q43994130 | Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. |
| Q33387265 | Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor |
| Q37718852 | Innate immunity to adenovirus |
| Q37215836 | Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration |
| Q54364641 | Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model. |
| Q34013719 | Lactoferrin protects against acetaminophen-induced liver injury in mice |
| Q46660799 | Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer |
| Q33950022 | Liver tissue engineering in the evaluation of drug safety |
| Q64378421 | Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver |
| Q36226761 | Naked DNA for liver gene transfer |
| Q28476268 | Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems |
| Q45882632 | Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation |
| Q45119497 | Rapid Kupffer cell death after intravenous injection of adenovirus vectors |
| Q33713401 | Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver |
| Q33225225 | Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting |
| Q47353872 | Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats |
| Q34004838 | Strategies to improve drug delivery across the blood-brain barrier |
| Q37503253 | Strategies to overcome host immunity to adenovirus vectors in vaccine development |
| Q41375421 | Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection. |
| Q33382953 | Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. |
| Q38614156 | Tropism-modification strategies for targeted gene delivery using adenoviral vectors |
| Q63384095 | Viruses and their uses in nanotechnology |
| Q45875332 | Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent |
| Q33915868 | beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2. |
Search more.